||Targets interleukin-23; for treatment of Crohn's disease; in phase II clinical trials (2015).
Amgen: AMG 139 is a human monoclonal antibody that neutralises IL-23 interaction with its receptor while sparing IL-12. It is being investigated as a treatment for a variety of inflammatory disorders. AMG 139 is being investigated in Phase 1 for Crohns disease, with lifecycle possibilities in psoriasis and other inflammatory conditions. (Manufacturer)